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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.04.044Objective: The REMATCH trial compared the use of left ventricular assist devices with
optimal medical management for patients with end-stage heart failure. When the trial
met its primary end point criteria in July 2001, left ventricular assist device therapy was
shown to significantly improve survival and quality of life. With extended follow-up, 2
critical questions emerge: (1) Did these benefits persist, and (2) did outcomes improve
over the course of the trial, given the evolving nature of the technology?
Methods: We analyzed survival in this randomized trial by using the product-limit
method of Kaplan and Meier. Changes in the benefits of therapy were analyzed by
examining the effect of the enrollment period.
Results: The survival rates for patients receiving left ventricular assist devices (n 68)
versus patients receiving optimal medical management (n 61) were 52% versus 28%
at 1 year and 29% versus 13% at 2 years (P .008, log-rank test). As of July 2003, 11
patients were alive on left ventricular assist device support out of a total 16 survivors
(including 3 patients receiving optimal medical management who crossed over to left
ventricular assist device therapy). There was a significant improvement in survival for
left ventricular assist device–supported patients who enrolled during the second half of
the trial compared with the first half (P .03). The Minnesota Living with Heart Failure
scores improved significantly over the course of the trial.
Conclusion: The extended follow-up confirms the initial observation that left ven-
tricular assist device therapy renders significant survival and quality-of-life benefits
compared with optimal medical management for patients with end-stage heart
failure. Furthermore, we observed an improvement in the survival of patients
receiving left ventricular assist devices over the course of the trial, suggesting the
effect of greater clinical experience.
Left ventricular assist devices (LVADs) have been in widespreadclinical use for a decade as a temporary device to support patientsawaiting cardiac transplantation.1-9 Successful experience for thisbridge-to-transplantation indication, particularly among those withprolonged periods of implantation, justified evaluating these devicesas long-term or destination therapies for chronic heart failure. The
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive
Heart Failure (REMATCH) trial recently showed that LVADs could improve both
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failure who are ineligible for cardiac transplantation.10,11
This intervention nearly halved (relative risk, 0.52; 95%
confidence limit, 0.34-0.78) the mortality seen in the control
population, who, despite receiving state-of-the-art medical
therapy, succumbed to their disease at a rate of 92% at 2
years. Even with a high frequency of serious adverse events
(AEs) from infection, bleeding, and device malfunction,
LVAD recipients had an improved survival rate and expe-
rienced a superior quality of life than their medical therapy
counterparts.11
Although the REMATCH trial met its predetermined
mortality end point (and, consequently, enrollment discon-
tinued) in July 2001, data collection continues for survivors.
We review here the extended survival and AE experience of
REMATCH patients, including an additional 125 patient-
months of experience for the medical arm (total patient-
months, 534) and 375 patient-months for the LVAD arm
(total patient-months, 1009). During the enrollment period
(1998-2001) in the REMATCH trial, the clinical manage-
ment of patients receiving LVADs evolved, and device
modifications were introduced. Therefore this article also
explores how these changes might have affected patient
outcomes. Specifically, we examine whether survival in the
LVAD arm improved over time and, if so, whether this
trend was unique to patients receiving LVADs or seen in
medically managed patients as well.
Methods
Trial Organization
The study was conducted in 21 experienced cardiac transplantation
centers under a cooperative agreement among Columbia Univer-
sity, Thoratec Inc, and the National Heart, Lung, and Blood
Institute of the National Institutes of Health. The trial was super-
vised by a steering committee and executed by an independent
Coordinating Center (International Center for Health Outcomes
and Innovation Research, Columbia University). An independent
morbidity and mortality committee adjudicated causes of death
and AEs. The National Institutes of Health appointed a Data and
Safety Monitoring Board to review trial progress. The US Food
and Drug Administration (FDA) granted an investigational device
exemption as a pivotal phase III trial. Participating institutional
review boards approved the protocol, and informed consent was
obtained for all patients.
Study Patients
We defined a subset of adults with chronic end-stage heart failure
and contraindications to transplantation. Entry criteria included the
following: (1) class IV New York Heart Association (NYHA)
symptoms for 90 days or greater despite attempted therapy with
angiotensin-converting enzyme inhibitors, diuretics, and digoxin
(subsequent criteria allowed for patients with class IIIB disease
taking inotropes for 14 of 28 days or with intra-aortic balloon
pumps); (2) left ventricular ejection fraction of 25% or less; and
(3) peak oxygen consumption of 14 mL · kg1 · min1 or less or
10 The Journal of Thoracic and Cardiovascular Surgery ● Januadocumented failure to wean intravenous inotropic therapy caused
by systolic blood pressure of less than 80 mm Hg, decreasing renal
function, or worsening symptoms with objective signs of deterio-
ration. Transplantation was contraindicated for at least one of the
following: age greater than 65 years, insulin-dependent diabetes
mellitus with end organ damage, chronic renal failure with a
sustained serum creatinine level of greater than 2.5 mg/dL for 90
days or more before randomization, or other significant comor-
bidities. Detailed exclusion criteria were reported previously.12
Study Design
We conducted a parallel design study in which patients were
randomly assigned to the vented electric Thoratec LVAD or opti-
mal medical management (OMM) in a 1:1 ratio. The randomiza-
tion was stratified by center and blocked to ensure ongoing equiv-
alence of group size. Eligibility was determined by site
investigators and confirmed by the coordinating center gatekeeper.
The unethical nature of sham operations and obvious device func-
tion precluded double-blind design. However, investigators were
masked to overall outcome data throughout enrollment, except for
the statisticians. In accordance with FDA requirements, Thoratec
received ongoing data for patients receiving LVADs but was
masked to all OMM data. The patients were seen monthly until the
time of death or up to a period of 24 visits (28 days) from the initial
enrollment for the measurement of all secondary end points, in-
cluding serious AEs and quality of life. After 24 visits, all patients
continue to be followed for survival.
Statistical Analysis
The primary end point was all-cause mortality compared by using
the log-rank statistic. We used Cox proportional-hazards regres-
sion to estimate hazard ratios and 95% confidence intervals and to
adjust for differences in baseline outcome predictors. Analyses
were both by intention to treat and as treated. We analyzed the
trends in survival by year of enrollment, which was not a prespeci-
fied analysis. We used the midpoint of LVAD enrollment as the
dividing point for comparing the 2 cohorts. AEs were adjudicated
as serious if they caused death or permanent disability, threatened
life, or required or prolonged hospitalization. Frequency of event
occurrence was analyzed by means of Poisson regression. Quality
of life and functional status were assessed by using the Minnesota
Living with Heart Failure (MLHF) questionnaire and the NYHA
classification. The MHLF questionnaire contains 21 questions
regarding the patients’ perceptions of the effects of heart failure on
their daily lives. The best score is 0, and the worst score is 105.13
Statistical testing was done on a longitudinal data set to account for
effect of time on treatment. NYHA scores were compared by using
the Fisher exact test. The July 2003 data set was used to compare
the survival experience, AEs, and quality of life of the LVAD and
OMM treatment groups.
Results
Patient Demographics
A total of 129 patients were enrolled in the study: 68
patients were randomized to ventricular assist device im-
plantation, and 61 patients were randomized to medical
management. The baseline characteristics, which capture,
ry 2005
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parable between the 2 groups in the full trial, as shown in
Table 1. The baseline characteristics of the patients receiv-
ing LVADs enrolled during the first half of the trial were
similar to those enrolled during the second half; for medi-
cally managed patients, all characteristics were similar, ex-
cept for age and the percentage of patients who had isch-
emic heart disease.
Survival
Figure 1 depicts the actuarial survival of both REMATCH
treatment groups on the basis of an intention-to-treat anal-
ysis (ie, based on randomization assignment regardless of
treatment crossover; P  .008). The 1-year survival was
52% (95% confidence limit [CL], 40%-63%) for patients
receiving LVADs versus 28% (95% CL, 17%-39%) for
medically managed patients, and the 2-year survival was
29% (95% CL, 19%-40%) versus 13% (95% CL, 5%-22%) for
the 2 groups, respectively. The median survival was 408 versus
150 days in the LVAD and OMM groups, respectively,
whereas the mean survival was 385 versus 246 days. As of July
2003 (the time of closure of the latest fully adjudicated data
TABLE 1. Baseline characteristics
Full trial
OMM
(n  61)
LVAD
(n  68)
P
value
Age (y) 68 8.2 66 9.1 .16
Male sex (% of patients) 82 78 .66
Ischemic cause of heart
failure (%)
69 78 .32
Left ventricular ejection
fraction (%)
17  4.5 17 5.2 .92
Blood pressure (mm Hg)
Systolic 103 17 101 15 .46 1
Diastolic 62 11 61  10 .99
Pulmonary capillary wedge
pressure (mm Hg)
24  7.4 25 9.9 .35
Cardiac index (L · min1 · m2) 2  0.6 1.9 1 .36
Heart rate (beats/min) 84 15 84  16 .8
Pulmonary vascular
resistance (Wood units)
3.2  1.8 3.4 1.8 .75
Quality of life, symptoms of
depression and functional
status
MLHF (total score) 75 17 75  18 .63
SF-36 (Physical
Functioning)
18  19 19  19 .67
SF-36 (Role Emotional) 25 38 33  42 .33
BDI 16 8.3 19 9.2 .18
NYHA classification
IIIb/IV {%/%}
1.6/98.4 2.9/97.1 1
LVAD, Left ventricular assist device; OMM, optimal medical management
NYHA, New York Heart Association.set), 11 patients from the original LVAD cohort and 5 from the
The Journal of Thoracoriginal OMM cohort were still living. Patients receiving med-
ical therapy were given the option of crossing over to LVAD
therapy in June 2001, when the primary end point criteria were
reached and LVAD therapy was recognized to offer a survival
advantage. Three of the 5 patients elected to do so, 1 patient
withdrew from the trial, and 1 patient opted to continue OMM.
In an as-treated analysis, in which patients receiving OMM
who crossed over to LVAD therapy were censored at the time
of crossover, the 2-year survival was 29% (95% CL, 19%-
40%) for patients receiving LVADs versus 13% (95% CL,
2%-17%) for patients receiving OMM.
Effect of Enrollment Time on Survival
To analyze whether time of enrollment affected survival in
the 2 treatment cohorts, we compared the results of patients
enrolled before and after January 1, 2000, the approximate
50% enrollment point of the trial. All but one center had
enrolled patients by that point. Figure 2 shows the compar-
ison of the 34 patients receiving LVADs who were enrolled
before (20th Century) and the 34 patients with LVADs who
were enrolled after (21st Century) January 1, 2000. The
LVAD OMM
e 2000
34)
After 2000
(n  34)
P
value
Before 2000
(n  35)
After 2000
(n  26)
P
value
 8.5 67.9 9.5 .16 65.8  9.3 71.1  5.3 .01
4 82 .56 80 84.8 .75
2 74 .56 57.14 84.62 .03
 5.1 16.8 5.5 .33 17.1  4.9 17.4  4.2 .86
 17.2 99.2 13.2 .35 103.3 20.6 102.2 10.9 .78
 9 59.9 11.3 .2 61.6 12 61.7 .96
 11 25 9.8 .98 23.3  6.7 24.4  8.3 .57
 0.6 1.9  0.6 .23 2  0.7 2.1 0.6 .56
 17.9 84.3 14.7 .89 84.3 14.3 83.12 16.52 .77
 1.8 3.8 2.0 .08 3.2  1.8 3.2  1.7 .93
 21 76.4 14.1 .55 76.5 16.2 71.5 17.9 .26
 22.4 14.7 13.7 .07 18.4 19.7 17.7 18.3 .88
 45.9 24.5 37 .09 21.9  37 29.5  40 .45
 9.4 18.4 9.2 .8 16.9  8.8 15.8  7.7 .62
97.1 2.9/97.1 1 0/100 3.9/96.2 .43
F, Minnesota Living with Heart Failure; BDI, Beck Depression Inventory;Befor
(n 
64.8
7
8
18.1
02.7
63.1
24.9
2
83.8
3.0
73.9
23.1
42.2
18.9
2.9/1-year survival in the 21st century subgroup was 59% (95%
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CL, 42%-75%), and in the 20th century group it was 44%
(95% CL, 27%-61%). At 2 years, the survival was 38%
(95% CL, 22%-55%) and 21% (95% CL, 7%-34%) in the
21st and 20th century subgroups, respectively. The overall
survival curves were significantly different, as determined by
using the log-rank test (P  .029). This difference was not
concentrated in the perioperative period; the 30-day survival
curves between the 2 cohorts were similar (P  .539).
Figure 3 compares the survival of the 35 patients receiv-
ing OMM enrolled before the millennium with the 26 pa-
tients enrolled after the millennium. The 1-year survival in
the late enrollment subgroup (21st century) was 35% (95%
CL, 16%-53%) compared with 23% (95% CL, 9%-37%) in
Figure 1. Kaplan-Meier
Figure 2. Kaplan-Meier survival curves for patients re
2000-2001 (P  .00293).the early enrollment subgroup (20th century). At 2 years,
12 The Journal of Thoracic and Cardiovascular Surgery ● Januathe survival was 29% (95% CL, 19%-40%) and 9% (95%
CL, 0%-16%) in the late and early subgroups, respectively.
The overall survival curves were not significantly different
(P  .255).
Causes of Death and AEs
Major causes of death in the LVAD arm were sepsis and
device failure, whereas in the medical arm by far the ma-
jority of patients die from progression of their ventricular
failure (Table 2). Patients receiving LVADs were a little
more than twice as likely to experience a serious AE as their
medical counterparts (Table 3). The most common AEs
among patients receiving OMM were ventricular arrhyth-
ival curve (P  .0077).
ng LVADs enrolled in 1998-1999 and those enrolled inceivimia, sepsis, local infection, and neurologic dysfunction. The
ry 2005
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and neurologic dysfunction. Neurologic dysfunction sub-
sumes stroke, transient ischemic attacks, and metabolic en-
cephalopathy. The majority of neurologic events were tran-
sient in nature.
Table 4 stratifies the AE rates for patients receiving
LVADs in the early (20th century) versus the late (21st
century) enrollment subgroup. The overall AE rate for the
late enrollment subgroup was significantly lower than for
the early subgroup. In particular, the rates per patient-year
of sepsis, renal failure, and pump housing, inflow, or out-
flow graft infections were significantly lower for those
patients enrolled during the second half of the trial.
Quality of Life
At baseline, nearly all patients (97%) were in NYHA class
IV. At 1 year, only 17% of surviving medically managed
patients improved to class I/II, whereas 71% of surviving
patients receiving LVADs improved to this level (P 
.0017). The MLHF score was significantly better for the
patients receiving LVADs over the course of the study (P
.007). The magnitude of difference at 1 year was 11 points
on the MLHF scale: 53 for medically managed patients and
42 for patients receiving LVADs (Figure 4).
Discussion
The REMATCH trial results, first reported in 2001, estab-
lished LVAD implantation as a viable option for patients
with end-stage heart failure.11 The 2 years of additional
observation on REMATCH patients reported here substan-
tiates the continuing survival benefit conferred by LVAD
support. LVAD treatment more than doubled the survival
seen at 2 years with OMM. Accounting for crossover among
Figure 3. Kaplan-Meier curves of OMM survival in pat
(P  .2551).patients receiving OMM through an as-treated analysis only
The Journal of Thoracincreases the survival benefit further. As of July 24, 2003,
the closure date for the data set analyzed here, 14 patients
were alive on LVAD support, including 3 crossover patients
from the medical therapy group, compared with only 2
survivors with native hearts (1 of whom was enrolled in
another heart-failure trial). The additional follow-up time of
the study established that the quality of life and functional
status of patients in the LVAD arm remained significantly
better than those of their medical counterparts. The differ-
ences in quality-of-life measurements observed here trans-
late into significant differences in activities of daily living
and emotional well-being. These improvements occurred
despite the fact that patients receiving LVADs were more
than twice as likely to experience AEs than medically
TABLE 2. Causes of death
LVAD OMM
LV dysfunction 1 52
Sepsis 21 1
LVAD failure 11 0
Other noncardiac cause 7 0
Cerebrovascular disease 7 0
Other cardiovascular 5 1
Pulmonary embolism 2 0
Acute myocardial infarction 0 1
Cardiac procedure 0 1
Perioperative bleeding 1 0
Unknown 2 0
Total 57 56
LVAD, Left ventricular assist device; OMM, optimal medical management;
LV, left ventricular.
enrolled in 1998-1999 and those enrolled in 2000-2001managed patients.
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transplantation, destination therapy is an entirely new use.14
In fact, the FDA only allowed bridging patients to be
discharged to their home environment as of 1996. Thus the
ambulatory experience with these patients was still rather
new when the REMATCH trial started, and the extended
experience led to changes in patient management, as well as
device modifications. During the trial, for example, locking
screw ring connectors were added to the inflow and outflow
grafts to avert disconnections, and outflow graft bend relief
was introduced to prevent kinking and the resultant inflow
valve incompetence. At the same time, changes in patient
management took effect, such as infection management
guidelines, which defined the choice of antimicrobial pro-
phylaxis and the use of abdominal binders to stabilize the
driveline exit site. Therefore we questioned whether these
changes had an effect on survival over the course of this trial.
We found that the time of enrollment was a significant
factor in determining survival. In fact, there was about a
15% improvement in survival rate both at 1 and 2 years
TABLE 3. Adverse events (AE)
No.
OMM LVAD
AE
Any AE 108 431
Neurodysfunction 5 30
Bleeding 3 41
Localized infection 10 26
Sepsis 10 35
Thromboembolism 3 6
Cardiac arrest 6 6
Ventricular arrhythmia 22 16
Supraventricular arrhythmia 1 8
Syncope 0 6
Nonperioperative MI 0 1
Renal failure 7 15
Chronic renal dysfunction 0 0
Hepatic failure 0 2
Psychiatric episode 0 2
Other 41 92
Perioperative MI 0 0
LVAD-specific AE
LVAD-related RVH 11
Perioperative bleeding 28
Percutaneous site infection 24
Pump housing infection 13
Device thrombosis 3
LVAD system failure 7
Suspected device malfunction 58
OMM, Optimal medical management; LVAD, left ventricular assist devi
hypertrophy.between the patients receiving LVADs who were enrolled
14 The Journal of Thoracic and Cardiovascular Surgery ● Januaduring the second half of the trial compared with those
enrolled during the first half. This finding is unlikely to be
a result of clinical center participation in the trial because all
but one clinical site was enrolling patients before January 1,
2000. It is also unlikely that these differences came from
better patient selection in the second half of the trial. The 2
LVAD cohorts were similar in all their baseline character-
istics. However, these groups did manifest differences in
overall AE rates, with the later enrolled cohort experiencing
significantly fewer overall AEs than the cohort enrolled
during the first half of the trial. These differences were
concentrated in the areas of sepsis, pump housing inflow
and outflow graft infections, and renal failure. Moreover,
bleeding, which is an important AE in this group of patients,
shows a trend toward improvement over the course of the
trial. Although we are limited by the small numbers of
patients, these data suggest that changes in patient manage-
ment (as, for instance, codified in the infection management
guidelines) had an effect during the REMATCH trial. More
generally, these data suggest that AE rates and survival
Rate
MM LVAD Ratio Lower CI Upper CI
2.85 6.32 2.21 1.79 2.73
0.13 0.44 3.33 1.29 8.57
0.08 0.60 7.58 2.35 24.47
0.26 0.38 1.44 0.70 2.99
0.26 0.51 1.94 0.96 3.92
0.08 0.09 1.11 0.28 4.43
0.16 0.09 0.55 0.18 1.72
0.58 0.23 0.40 0.21 0.77
0.03 0.12 4.44 0.55 35.47
0.00 0.09
0.00 0.02
0.19 0.22 1.19 0.48 2.91
0.00 0.00
0.00 0.03
0.00 0.03
1.08 1.35 1.24 0.86 1.80
0.00 0.00
0.16
0.41
0.35
0.19
0.04
0.10
0.85
I, confidence interval; MI, myocardial infarction; RVH, right ventricularO
ce; Coutcomes can be improved as we mature in our experience
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LVAD experience, the time-stratified survival curves in the
medically managed arm were not significantly different.
Although there were some important medical therapeutic
advances for patients with heart failure during the
REMATCH trial period, such as the confirmation of the
value of -blockers and spironolactone, these interventions
do not address patients with the severity of heart failure seen
in the REMATCH population.15 Despite differences in 2 of
the baseline characteristics (age and cause of heart failure)
in time-stratified medical cohorts, it is unlikely that these
differences would mask a true survival difference of the
magnitude seen in the LVAD arm. However, one must keep
in mind the limitations of this study. In particular, this
comparison is a post hoc analysis of changes in survival
over time. In addition, the limited sample size in this sub-
group analysis affects our ability to make adequately pow-
ered comparisons for each of the AE types.
The results of the REMATCH trial have led to FDA
approval of the Heartmate VE for destination therapy in
November 2002, and in October 2003, the Center for Medi-
care and Medicaid Services decided to cover and reimburse
TABLE 4. Adverse events (AE)
Before 2000*
No. Rate
Any 232 7.65
Neurodysfunction 14 0.46
Bleeding 22 0.73
Localized infection 13 0.43
Sepsis 24 0.79
Thromboembolism 3 0.10
Cardiac arrest 6 0.20
Ventricular arrhythmia 6 0.20
Supraventricular arrhythmia 4 0.13
Syncope 1 0.03
Nonperioperative bleeding 0 0.00
Renal failure 12 0.40
Chronic renal 0 0.00
Hepatic failure 1 0.03
Psychiatric episode 1 0.03
Other AE 48 1.58
Perioperative MI 0 0.00
LVAD-related RHF 4 0.13
Perioperative bleeding 17 0.56
Percutaneous site infection 13 0.43
Pump housing infection 11 0.36
Device thrombosis 0 0.00
LVAD system failure 4 0.13
Suspected LVAD failure 28 0.92
CI, Confidence interval; MI, myocardial infarction; LVAD, left ventricular a
*11,078 follow-up days.
†13851 follow-up days.LVADs for this indication. With these regulatory decisions,
The Journal of Thoracthe stage is set for wider dissemination of these devices. We
Figure 4. Disease-specific quality of life at 12 months. The MLHF
scale range is 0 (best) to 105 (worst). The MLHF score was
significantly better for the patients receiving LVADs over the
course of the study (P  .007). The magnitude of difference at 1
year was 11 points on the MLHF scale: 53 for medically managed
patients and 42 for patients receiving LVADs.
fter 2000† Comparison
Rate Ratio Lower CI Upper CI
5.25 1.46 1.21 1.76
0.42 1.09 0.53 2.24
0.50 1.45 0.95 2.20
0.34 1.25 0.58 2.70
0.29 2.73 1.34 5.57
0.11 0.94 0.21 4.19
0.00
0.26 0.75 0.27 2.06
0.11 1.25 0.31 5.00
0.13 0.25 0.03 2.14
0.03 0.00
0.08 5.00 1.41 17.72
0.00
0.03 1.25 0.08 19.99
0.03 1.25 0.08 19.99
1.16 1.36 0.91 2.05
0.00
0.18 0.71 0.21 2.44
0.29 1.93 0.91 4.13
0.29 1.48 0.66 3.30
0.05 6.88 1.52 31.03
0.08 0.00
0.08 1.67 0.37 7.45
0.79 1.17 0.70 1.95
device; RHF, right heart failure.A
No.
199
16
19
13
11
4
0
10
4
5
1
3
0
1
1
44
0
7
11
11
2
3
3
30
ssistanticipate significant and steady improvement in survival
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care of these patients and as device modifications are intro-
duced into practice. An important factor in such learning
will be our ability to track changes in patient management
and device modifications and how they affect patient out-
comes. Furthermore, as new LVADs emerge as potential
destination therapy devices, our ability to collect data con-
cerning improved device design and patient outcome would
be imperative for a long-term success of destination therapy.
This argues for international participation of LVAD clinical
centers and device manufacturers in a clinical registry.
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Discussion
Dr Stephen Westaby (Oxford, United Kingdom). REMATCH is a
landmark clinical trial. The clear survival advantage for patients
receiving LVADs now justifies the use of circulatory support well
beyond the transplant setting. By means of randomization,
16 The Journal of Thoracic and Cardiovascular Surgery ● JanuaREMATCH also served to define the dismal natural history of
advanced heart failure and to provide reliable outcome data for a
first-generation blood pump. Patient enrollment was clearly diffi-
cult. The patients had to be nontransplant eligible, but 20 different
centers had different eligibility criteria. One patient underwent
transplantation at the end of this trial. The initial recruitment was
around 2 patients per center per year, and I would suggest that a
subsequent relaxation of entry criteria might explain some of the
findings in this presentation.
The majority of patients were already receiving inotropes,
balloon pump support, or both. The trial was analogous to ran-
domizing Titanic patients to a lifeboat or the sea. Apart from the
primary end point, some of the outcomes were disappointing.
Only half of the patients receiving LVADs survived for 1 year.
On the Minnesota Scale, the quality of life was not greatly im-
proved by the LVAD. It takes 3 months to recover from a major
heart operation, and as anticipated, many experienced chronic
infection or neurologic events. Ten of 68 LVADs were replaced,
and at last follow-up, 2 of the survivors had actually had a third
LVAD. Patients receiving LVADs spent one fifth of their survival
period in the hospital, and lifetime use will only prove economi-
cally viable if this strategy keeps patients out of the hospital.
The current presentation does not add substantially to the
outstanding New England Journal of Medicine article. The argu-
ment that LVAD survival improved by 6 weeks during the course
of the trial is not compelling. I think adjusted entry criteria and
progressively more careful patient selection might have accounted
for the improvement.
My first question is as follows: Could you elaborate on im-
provements in the LVAD itself and in postoperative management?
Why did these not affect the 30-day mortality? Would you also
comment on the durability of the HeartMate LVAD? I think the
main question now, is whether, after REMATCH, we move for-
ward with mechanical circulatory support. I would say that at
present there are at least 10 continuous flow pumps under devel-
opment or in clinical practice. These LVADs are much smaller and
can be implanted with less perioperative morbidity, fewer compli-
cations, and earlier hospital discharge. Infection in these new
pumps is uncommon.
Our first patient receiving a lifetime axial flow pump is now 3
years after implantation, in NYHA class I, and fully employed.
Others are following in this course. He travels internationally,
visits Washington, and talks to the FDA about permanent support.
The other aspect is that the partially unloaded native heart
continues to function and often improves with this type of LVAD,
and therefore the patient is not entirely dependent on either his
own heart or the pump.
I think improved safety justifies implantation before inotrope
dependency, and new adjuvant therapies might promote and sus-
tain myocardial recovery.
With the conclusion of REMATCH, it is probably time to plan
REMATCH II with second-generation devices and begin implant-
ing them before terminal decline.
I would like to congratulate Dr Park, Dr Rose, and all the
colleagues associated with the REMATCH trial.
Dr Park. Thank you, Dr Westaby, for your wonderful com-
ments. I concur with many of the things that you said, and I think
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Pyou have a good insight into this study. I would like to respond to
your comments. I might differ in some aspects.
This was a prospective randomized trial. The entry criteria were
changed during the course of the trial because we had a less-than-
anticipated enrollment initially; the number of patients who actu-
ally qualified under the new criteria was small. Unlike the surgical
cohort, we did not see any survival change during the course of the
trial within the medical group. Had we influenced patients’ out-
come by changing enrollment criteria, we would expect that it
would have affected both groups and not just the surgical group, as
observed in this randomized trial. Furthermore, the 2-year survival
outcome has improved from 0% (PREMATCH) to 21% (first half
of REMATCH) and then to 37% (second half of REMATCH) with
the same LVAD system. This seems to reflect the benefit of
improved management of these patients. Device modifications,
such as locking screw and outflow bend relief, are minor changes
in my mind to affect survival outcome in any meaningful way.
The REMATCH investigators participating in the surgical
group came up with the infection prevention protocols, and we also
had conferences about how to manage their nutritional needs. I
would say that those are some of the things that we learned as a
community caring for these patients. This is the first time this type
of device has been tried as a destination therapy in very sick
persons, and I think we will continue to learn over time.
Durability is a major problem, and in fact, every patient at our
institution who is currently alive had to undergo device change-
outs. I am convinced that device change-out is a doable task with
acceptable risk. Nevertheless, I do concur with you that we need to
have a more reliable and durable device to have long-term success
in destination therapy. Perhaps the next-generation axial flow
pumps and other things might be the answer, and I agree that is
where we should be headed.
I am delighted to hear that you have a patient who has been
supported on an axial flow pump over 3 years. Perhaps that is the
right technology to adopt. But right now, for many people who are
dying from advanced heart failure, the REMATCH trial has for the
first time evaluated a new technology in a scientific format in
which we have evidence-based medicine that we could practice
until the next trial and new devices come along.
In terms of myocardial recovery, it is hard to speculate that a
particular device is more effective over another. We are just
learning about myocardial recovery. Last year, I had 5 patients in
whom I was able to explant devices. We do not know whether an
axial flow pump or another pump would be better, but we should
be open minded about that.
Dr O. Howard Frazier (Houston, Tex). The REMATCH trial
was a colossal endeavor by Dr Rose and his team to correlate a
group of patients that we could earmark for the future of these
studies. I think the miraculous thing was that any of them survived.
The Journal of ThoracIt was interesting that the first 3 months’ survival was the same for
both the medical and the surgical group, and the surgical group
underwent surgical intervention. I have implanted over 200 Heart-
Mates, and I had 3 early deaths with one 2-year survival. Therefore
I think what should be stressed by the REMATCH trial is that this
medical group should no longer be subjected to a rather hopeless
future.
As to the quality-of-life data, I would like for you to comment on
how many of the LVAD survivors are now currently outpatients and
how many of the medically treated group are currently outpatients.
As to the patients receiving axial flow pumps, not a one of them
would survive this type of randomization. It is a tremendous tour
de force of surgery of the groups, particularly in Minnesota and
Utah, that were able to achieve very good survival with this.
Dr Park. Thanks, Dr Frazier, for your comments. I think you
are right. There were some concerns about the trial initially be-
cause we were dealing with such a sick group of patients. Often,
we did not have enough time to evaluate them properly, and that
might have resulted in early deaths.
The first 2 patients I implanted the device in at the University
of Minnesota died. One patient ended up having a massive pul-
monary emboli, which was misinterpreted as worsening chronic
heart failure. The second patient did well with the operation, but
she died of cerebral hyperperfusion. I was very happy to see that
her cardiac index went from somewhere around 1.6, I suppose, to
2.5 and 3, and I thought the patient was doing very well. It turned
out that she was having too much acute change in cerebral perfu-
sion, which resulted in profound cerebral edema. Those problems
have been dealt with in subsequent patients. We have reported this
phenomenon of hyperperfusion-related problems in the literature.
When you deal with such a sick group of patients with high
baseline mortality, therapeutic efficacy of VAD therapy might not
be demonstrable until some time beyond 3 months.
One of the problems as a presenter dealing with a multicenter
trial is that you do not really have hands-on experience with every
patient. Therefore I will tell you only about my experience at the
University of Minnesota, about patients receiving optimal medical
management versus those receiving devices and how they are
doing with quality of life and survival.
We have one survivor in the optimal medical management
group, and he is currently living with the ventricular assist device
as a crossover patient. Five other patients have all died within
about 6 months of enrollment. Of 8 device implantations, includ-
ing one crossover, the first 2 died. The subsequent 6 all went home
healthy with devices. All 6 patients have required device change-
outs, and 2 patients died after device change-out. The remaining 4
patients are currently alive with devices and are all at home in
NYHA functional class I.
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